IMMUNO CARE ADVANCED COMBINATION PRODUCT POWDER

Indications

• Alcohol withdrawal syndrome
• Disinfection of skin prior to surgical procedures
• Antiseptic for minor cuts and abrasions
• Solvent in pharmaceutical preparations

Dosage

Children: Refer to the BNF for Children for appropriate paediatric dosing information.

Adults: Refer to specific clinical guidelines and the BNF for detailed dosage recommendations based on the indication.

Mechanism of action

Ethanol affects brain neurons by altering their membranes, ion channels, enzymes, and receptors. It binds to GABA receptors, enhancing inhibitory effects, and inhibits NMDA receptors for glutamate. It acts as an osmolyte, disrupting osmotic balance across cell membranes, and interacts with a variety of neurotransmitters, leading to altered signaling pathways.

Pharmacodynamics

Ethanol can cause cell injury through dehydration and precipitation of the cytoplasm. This property contributes to its bacteriocidal and antifungal effects. The majority of ethanol is oxidized in the body, with important roles in sedative effects and as a co-solvent in drug formulations. It also produces neurotoxic effects when injected near nerve tissues.

Pharmacokinetics

Ethanol is rapidly absorbed from the gastrointestinal tract, reaching peak blood concentrations within 30 to 90 minutes after ingestion. It is primarily metabolized in the liver by alcohol dehydrogenase and other enzymes, with a half-life that varies based on factors such as dosage and individual metabolism. Elimination is primarily through hepatic metabolism, with a small percentage excreted unchanged in urine and breath.

Adverse effects

• Drowsiness
• Dizziness
• Nausea
• Vomiting
• Headache
• Respiratory depression
• Hypotension
• Acute pancreatitis
• Alcoholic hepatitis
• Alcohol use disorder

Interactions

• Increased sedative effects with benzodiazepines
• Increased risk of gastrointestinal bleeding with NSAIDs
• Potentially increased effects of anticoagulants like warfarin
• Interactions with disulfiram leading to unpleasant reactions

Precautions

• Caution in patients with liver disease
• Caution in elderly patients due to increased sensitivity
• Use with caution in patients with a history of substance abuse
• Monitor for signs of respiratory depression when used with other CNS depressants

Pregnancy

Ethanol is contraindicated during pregnancy due to the risk of fetal alcohol spectrum disorders.

Breast-feeding

Alcohol is excreted in breast milk; caution is advised as it may affect the infant.

Storage

Store in a cool, dry place away from direct sunlight and heat sources. Keep tightly closed.

Formulations

• Oral solutions
• Injectable solutions
• Topical preparations

Indications

• Alcohol use disorder
• Sedation
• Antiseptic for skin and surfaces
• Solvent in pharmaceutical formulations

Dosage

Children: Refer to the BNF for Children for appropriate pediatric dosing recommendations.

Adults: Refer to the BNF for specific dosing guidelines, as dosages may vary based on the indication and formulation used.

Mechanism of action

Ethanol affects the brain's neurons by altering their membranes, ion channels, enzymes, and receptors. It binds to GABA receptors, enhancing inhibitory neurotransmission, and inhibits NMDA receptors, disrupting excitatory neurotransmission. This dual action leads to its sedative effects and contributes to its anti-infective properties by acting as a dehydrating agent that disrupts osmotic balance across cell membranes.

Pharmacodynamics

Ethanol induces cell injury through dehydration and cytoplasmic precipitation, which underlies its bactericidal and antifungal actions. It is metabolized primarily by alcohol dehydrogenase in the liver, with 90 to 98% of ingested ethanol being oxidized. Ethanol also modulates neurotransmitter receptor activity, particularly at GABA and glutamate receptors, influencing various physiological responses.

Pharmacokinetics

Ethanol is rapidly absorbed from the gastrointestinal tract, with peak blood concentrations occurring approximately 30 to 90 minutes after ingestion. It is distributed throughout body tissues, with a volume of distribution that varies among individuals. Ethanol is primarily metabolized in the liver via alcohol dehydrogenase and is excreted through urine, breath, and sweat.

Contra-indications

• Hypersensitivity to ethanol or any of the excipients
• Severe liver disease
• Acute pancreatitis
• Pregnancy

Adverse effects

• Drowsiness
• Dizziness
• Nausea
• Vomiting
• Headache
• Impaired motor skills
• Tolerance and dependence with chronic use
• Neurotoxicity at high doses

Interactions

• CNS depressants may enhance sedative effects of ethanol
• Alcohol may interfere with the metabolism of other drugs through inhibition of liver enzymes
• Use with caution in combination with other substances that affect the liver

Precautions

• Use with caution in patients with a history of substance abuse
• Monitor for signs of alcohol intolerance or allergy
• Assess liver function before use
• Avoid use before activities requiring mental alertness

Pregnancy

Ethanol is contraindicated in pregnancy due to the risk of fetal alcohol syndrome and other developmental disorders.

Breast-feeding

Ethanol can enter breast milk and may affect the infant, thus should be used with caution or avoided during breastfeeding.

Storage

Store in a cool, dry place, away from light and heat. Keep out of reach of children.

Formulations

• Oral solutions
• Topical solutions
• Injectable solutions

Indications

• Autoimmune disorders
• Organ transplantation
• Certain malignancies
• Chronic inflammatory diseases
• Allergic conditions

Dosage

Children: Refer to specific drug guidelines as dosing varies significantly based on the drug class and indication.

Adults: Refer to specific drug guidelines as dosing varies significantly based on the drug class and indication.

Mechanism of action

Immunomodulatory drugs work through various mechanisms, including the modulation of cytokine production, alteration of immune cell signaling pathways, and direct effects on immune cells such as T cells and B cells. For instance, they may inhibit the activation of nuclear factor kappa B (NF-kB) or the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, which are crucial for inflammatory responses.

Pharmacodynamics

The pharmacodynamics of immunomodulatory drugs vary significantly depending on their specific class and target. Generally, these medications can either enhance the immune response (immunostimulants) or suppress it (immunosuppressants). The effects can lead to increased susceptibility to infections or improved conditions in autoimmune diseases. The therapeutic effects are often seen after a period of treatment as the immune system gradually adjusts.

Pharmacokinetics

Immunomodulatory drugs are absorbed through various routes, including oral and parenteral administration. Their bioavailability, distribution, metabolism, and excretion depend on the specific drug. For instance, some are metabolized in the liver and may have variable half-lives, necessitating careful monitoring to avoid toxicity. Drug interactions can also impact their pharmacokinetics.

Pregnancy

Immunosuppressive drugs may pose risks during pregnancy, including potential teratogenic effects. Consultation with a healthcare provider is essential.

Breast-feeding

Caution is advised as immunosuppressive agents can be excreted in breast milk and may affect a nursing infant.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Indications

• Used in agriculture to regulate plant growth
• Commonly applied to cereal crops to prevent lodging
• Enhances crop yield and stability

Mechanism of action

Chlormequat chloride acts at the nicotinic receptor site of the neuromuscular junction, functioning as a depolarizing agent. This action leads to initial muscular excitation which is then followed by muscle weakness. The acute toxicity of chlormequat chloride may result in respiratory arrest, and its effects can vary by species due to differing sensitivities to depolarizing neuromuscular blockers.

Pharmacodynamics

Chlormequat chloride inhibits gibberellin biosynthesis, a key hormone in plant growth regulation, which leads to reduced cell elongation and overall dwarfing of plants. This mechanism helps enhance crop stability and yield by minimizing the risk of lodging in cereals, thus promoting a more efficient harvest.

Pharmacokinetics

The pharmacokinetics of chlormequat chloride in plants involves absorption, translocation, and metabolism within plant tissues. It is rapidly absorbed and translocated throughout the plant, with a relatively short half-life, leading to effective growth regulation while minimizing residues in harvested products.

Pregnancy

No adequate and well-controlled studies in pregnant women have been conducted. Use only if clearly needed.

Breast-feeding

It is not known whether chlormequat chloride is excreted in human milk. Caution should be exercised when administering to a nursing mother.

Storage

Store in a cool, dry place. Keep container tightly closed.

Mechanism of action

Ethanol affects the brain’s neurons in several ways. It alters their membranes as well as their ion channels, enzymes, and receptors. Alcohol also binds directly to the receptors for acetylcholine, serotonin, GABA, and the NMDA receptors for glutamate. The sedative effects of ethanol are mediated through binding to GABA receptors and glycine receptors (alpha 1 and alpha 2 subunits). It also inhibits NMDA receptor functioning. In its role as an anti-infective, ethanol acts as an osmolyte or dehydrating agent that disrupts the osmotic balance across cell membranes. ... Ethanol is known to affect a large number of membrane proteins that participate in signaling pathways such as neurotransmitter receptors, enzymes, and ion channels, and there is extensive evidence that ethanol interacts with a variety of neurotransmitters. The major actions of ethanol involve enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) at GABAa receptors and blockade of the N-methyl-D-aspartate (NMDA) subtype of glutamate, an excitatory amine acid (EAA) receptor. Animal studies indicate that the acute effects of ethanol result from competitive inhibition of glycine binding to NMDA receptor and disruption of glutamatergic neurotransmission by inhibiting the response of the NMDA receptor. Persistent glycine antagonism and attenuation of glutamatergic neurotransmission by chronic ethanol exposure results in tolerance to ethanol by enhancing EAA neurotransmission and NMDA receptor upregulation. The latter appears to involve selective increases in NMDA R2B subunit concentrations and other molecular changes in specific brain loci. The abrupt withdrawal of ethanol thus produces a hyperexcitable state that leads to the ethanol withdrawal syndrome and excitotoxic neuronal death. GABA-mediated inhibition, which normally acts to limit excitation, is eliminated during ethanol withdrawal syndrome and further intensifies this excitation. In addition, NMDA receptors function to inhibit the release of dopamine in the nucleus accumbens and mesolimbic structures, which modulate the reinforcing action of addictive xenobiotics such as ethanol. By inhibiting NMDA receptor activity, ethanol could increase dopamine release from the nucleus accumbens and ventral tegmental area and could thus create dependence. Chronic ethanol administration also results in tolerance, dependence, and an ethanol withdrawal syndrome, mediated, in part, by desensitization and or downregulation of GABAa receptors. The development of alcoholic ketoacidosis (AKA) requires that a combination of physical and physiologic events occur. The normal response to starvation and depletion of hepatic glycogen stores is for amino acids to be converted to pyruvate. Pyruvate can serve as a substrate for gluconeogenesis, be converted to acetyl-CoA, which can enter the Krebs cycle or can be utilized in various biosynthetic pathways (eg, fatty acid, ketone bodies, cholesterol, and acetylcholine) ... Ethanol metabolism generates NADH, resulting in an excess of reducing potential. This high redox state favors the conversion of pyruvate to lactate, diverting pyruvate from being a substrate for gluconeogenesis. To compensate for the lack of normal metabolic substrates, the body mobilizes fat from adipose tissue and increased fatty acid metabolism as an alternative source of energy. This response is mediated by a decrease in insulin and an increased secretion of glucagon, catecholamines, growth hormone, and cortisol. Fatty acid metabolism results in the formation of acetyl-CoA and it combines with the excess acetate that is generated from ethanol metabolism to form acetoacetate. Most of the acetoacetate is reduced to beta-hydroxybutyrate due to the excess reducing potential or high redox state of the cell. Volume depletion interferes with the renal elimination of acetoacetate and beta-hydroxybutyrate, and contributes to the acidosis. An elevated lactate concentration may result from shunting from pyruvate or

Pharmacodynamics

Alcohol produces injury to cells by dehydration and precipitation of the cytoplasm or protoplasm. This accounts for its bacteriocidal and antifungal action. When alcohol is injected in close proximity to nerve tissues, it produces neuritis and nerve degeneration (neurolysis). Ninety to 98% of ethanol that enters the body is completely oxidized. Ethanol is also used as a cosolvent to dissolve many insoluble drugs and to serve as a mild sedative in some medicinal formulations. Ethanol also binds to GABA, glycine, NMDA receptors and modulates their effects. Ethanol is also metabolised by the hepatic enzyme alcohol dehydrogenase.

Mechanism of action

Ethanol affects the brain’s neurons in several ways. It alters their membranes as well as their ion channels, enzymes, and receptors. Alcohol also binds directly to the receptors for acetylcholine, serotonin, GABA, and the NMDA receptors for glutamate. The sedative effects of ethanol are mediated through binding to GABA receptors and glycine receptors (alpha 1 and alpha 2 subunits). It also inhibits NMDA receptor functioning. In its role as an anti-infective, ethanol acts as an osmolyte or dehydrating agent that disrupts the osmotic balance across cell membranes. ... Ethanol is known to affect a large number of membrane proteins that participate in signaling pathways such as neurotransmitter receptors, enzymes, and ion channels, and there is extensive evidence that ethanol interacts with a variety of neurotransmitters. The major actions of ethanol involve enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) at GABAa receptors and blockade of the N-methyl-D-aspartate (NMDA) subtype of glutamate, an excitatory amine acid (EAA) receptor. Animal studies indicate that the acute effects of ethanol result from competitive inhibition of glycine binding to NMDA receptor and disruption of glutamatergic neurotransmission by inhibiting the response of the NMDA receptor. Persistent glycine antagonism and attenuation of glutamatergic neurotransmission by chronic ethanol exposure results in tolerance to ethanol by enhancing EAA neurotransmission and NMDA receptor upregulation. The latter appears to involve selective increases in NMDA R2B subunit concentrations and other molecular changes in specific brain loci. The abrupt withdrawal of ethanol thus produces a hyperexcitable state that leads to the ethanol withdrawal syndrome and excitotoxic neuronal death. GABA-mediated inhibition, which normally acts to limit excitation, is eliminated during ethanol withdrawal syndrome and further intensifies this excitation. In addition, NMDA receptors function to inhibit the release of dopamine in the nucleus accumbens and mesolimbic structures, which modulate the reinforcing action of addictive xenobiotics such as ethanol. By inhibiting NMDA receptor activity, ethanol could increase dopamine release from the nucleus accumbens and ventral tegmental area and could thus create dependence. Chronic ethanol administration also results in tolerance, dependence, and an ethanol withdrawal syndrome, mediated, in part, by desensitization and or downregulation of GABAa receptors. The development of alcoholic ketoacidosis (AKA) requires that a combination of physical and physiologic events occur. The normal response to starvation and depletion of hepatic glycogen stores is for amino acids to be converted to pyruvate. Pyruvate can serve as a substrate for gluconeogenesis, be converted to acetyl-CoA, which can enter the Krebs cycle or can be utilized in various biosynthetic pathways (eg, fatty acid, ketone bodies, cholesterol, and acetylcholine) ... Ethanol metabolism generates NADH, resulting in an excess of reducing potential. This high redox state favors the conversion of pyruvate to lactate, diverting pyruvate from being a substrate for gluconeogenesis. To compensate for the lack of normal metabolic substrates, the body mobilizes fat from adipose tissue and increased fatty acid metabolism as an alternative source of energy. This response is mediated by a decrease in insulin and an increased secretion of glucagon, catecholamines, growth hormone, and cortisol. Fatty acid metabolism results in the formation of acetyl-CoA and it combines with the excess acetate that is generated from ethanol metabolism to form acetoacetate. Most of the acetoacetate is reduced to beta-hydroxybutyrate due to the excess reducing potential or high redox state of the cell. Volume depletion interferes with the renal elimination of acetoacetate and beta-hydroxybutyrate, and contributes to the acidosis. An elevated lactate concentration may result from shunting from pyruvate or

Pharmacodynamics

Alcohol produces injury to cells by dehydration and precipitation of the cytoplasm or protoplasm. This accounts for its bacteriocidal and antifungal action. When alcohol is injected in close proximity to nerve tissues, it produces neuritis and nerve degeneration (neurolysis). Ninety to 98% of ethanol that enters the body is completely oxidized. Ethanol is also used as a cosolvent to dissolve many insoluble drugs and to serve as a mild sedative in some medicinal formulations. Ethanol also binds to GABA, glycine, NMDA receptors and modulates their effects. Ethanol is also metabolised by the hepatic enzyme alcohol dehydrogenase.

Mechanism of action

Chlormequat chloride has been reported in the literature to act at the nicotinic receptor site of the neuromuscular junction. The test material may act as a depolarizing agent at this site, leading to muscular excitation followed by muscle weakness. Acute toxicity may lead to respiratory arrest. Acute toxicity of chlormequat chloride has also been reported to differ by species, which is likely due to sensitivity to depolarizing neuromuscular blockers.